- |||||||||| AMG 794 / Amgen
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov) - Jul 8, 2024
P1, N=3, Terminated,
N=98 --> 3 | Trial completion date: Feb 2028 --> Dec 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Dec 2023; Amgen has made the business decision to discontinue development of AMG 794. The safety profile of AMG 794 remains unchanged.
- |||||||||| AMG 794 / Amgen
Enrollment open, Trial completion date, Trial primary completion date, Metastases: A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov) - Oct 10, 2023
P1, N=98, Recruiting,
The safety profile of AMG 794 remains unchanged. Active, not recruiting --> Recruiting | Trial completion date: Jun 2027 --> Feb 2028 | Trial primary completion date: Dec 2025 --> Apr 2026
- |||||||||| AMG 794 / Amgen
Enrollment closed, Metastases: A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov) - May 10, 2023
P1, N=98, Active, not recruiting,
Active, not recruiting --> Recruiting | Trial completion date: Jun 2027 --> Feb 2028 | Trial primary completion date: Dec 2025 --> Apr 2026 Recruiting --> Active, not recruiting
- |||||||||| AMG 794 / Amgen
Enrollment open, Metastases: A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov) - Mar 6, 2023
P1, N=98, Recruiting,
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| AMG 794 / Amgen
Trial completion date, Trial primary completion date, Metastases: A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov) - Dec 12, 2022
P1, N=98, Not yet recruiting,
Not yet recruiting --> Recruiting Trial completion date: Nov 2027 --> Feb 2027 | Trial primary completion date: May 2026 --> Aug 2025
- |||||||||| AMG 794 / Amgen
Trial completion date, Trial primary completion date, Metastases: A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov) - Nov 28, 2022
P1, N=98, Not yet recruiting,
Trial completion date: Nov 2027 --> Feb 2027 | Trial primary completion date: May 2026 --> Aug 2025 Trial completion date: Jun 2027 --> Nov 2027 | Trial primary completion date: Dec 2025 --> May 2026
- |||||||||| AMG 794 / Amgen
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov) - Aug 1, 2022
P1, N=98, Not yet recruiting,
Trial completion date: Jun 2027 --> Nov 2027 | Trial primary completion date: Dec 2025 --> May 2026 Trial completion date: May 2026 --> Jun 2027 | Initiation date: May 2022 --> Oct 2022 | Trial primary completion date: Jul 2024 --> Dec 2025
|
